Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Galli

Showing results (331-340 of 354) with videos related to

Pageof 36
Sort By:
Frontiers in Immunology|October 7, 2022
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLCDiego Signorelli, Patrizia Ghidotti, Claudia Proto, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Frontiers in Psychology|July 10, 2023
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternativesSerena Oliveri, Lucilla Lanzoni, Jorien Veldwijk, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Clinical Lung Cancer|January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialClaudio Vernieri, Diego Signorelli, Giulia Galli, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Cancers|December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation CohortArsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Clinical Lung Cancer|August 10, 2022
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung CancerGiulia Galli, Paola Antonia Corsetto, Claudia Proto, et al.
Pageof 36

Showing results (331-340 of 354) with videos related to

Sort By:
Pageof 36
Frontiers in Immunology|October 7, 2022
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLCDiego Signorelli, Patrizia Ghidotti, Claudia Proto, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Frontiers in Psychology|July 10, 2023
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternativesSerena Oliveri, Lucilla Lanzoni, Jorien Veldwijk, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Clinical Lung Cancer|January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialClaudio Vernieri, Diego Signorelli, Giulia Galli, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Cancers|December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation CohortArsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Clinical Lung Cancer|August 10, 2022
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung CancerGiulia Galli, Paola Antonia Corsetto, Claudia Proto, et al.
Pageof 36